GB0309221D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
GB0309221D0
GB0309221D0 GBGB0309221.0A GB0309221A GB0309221D0 GB 0309221 D0 GB0309221 D0 GB 0309221D0 GB 0309221 A GB0309221 A GB 0309221A GB 0309221 D0 GB0309221 D0 GB 0309221D0
Authority
GB
United Kingdom
Prior art keywords
novel compounds
novel
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0309221.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB0309221.0A priority Critical patent/GB0309221D0/en
Publication of GB0309221D0 publication Critical patent/GB0309221D0/en
Priority to BRPI0409622-3A priority patent/BRPI0409622A/pt
Priority to MXPA05011365A priority patent/MXPA05011365A/es
Priority to PCT/EP2004/004244 priority patent/WO2004094430A1/en
Priority to CA002523291A priority patent/CA2523291A1/en
Priority to CNA2004800175617A priority patent/CN1809573A/zh
Priority to US10/553,878 priority patent/US20060229302A1/en
Priority to JP2006505223A priority patent/JP2006524206A/ja
Priority to AU2004232475A priority patent/AU2004232475B2/en
Priority to RU2005136370/04A priority patent/RU2005136370A/ru
Priority to KR1020057019979A priority patent/KR20050111797A/ko
Priority to EP04728567A priority patent/EP1620438A1/en
Priority to ZA200508041A priority patent/ZA200508041B/en
Priority to MA28563A priority patent/MA27674A1/fr
Priority to CO05107375A priority patent/CO5700829A2/es
Priority to NO20055442A priority patent/NO20055442L/no
Priority to IS8135A priority patent/IS8135A/is
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/06—Peri-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
GBGB0309221.0A 2003-04-23 2003-04-23 Novel compounds Ceased GB0309221D0 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
GBGB0309221.0A GB0309221D0 (en) 2003-04-23 2003-04-23 Novel compounds
EP04728567A EP1620438A1 (en) 2003-04-23 2004-04-21 Tricyclic indole derivatives and their use in the treatment of alzheimer's disease
AU2004232475A AU2004232475B2 (en) 2003-04-23 2004-04-21 Tricyclic indole derivatives and their use in the treatment of alzheimer's disease
KR1020057019979A KR20050111797A (ko) 2003-04-23 2004-04-21 트리시클릭 인돌 유도체 및 알츠하이머병의 치료에서의그의 용도
PCT/EP2004/004244 WO2004094430A1 (en) 2003-04-23 2004-04-21 Tricyclic indole derivatives and their use in the treatment of alzheimer’s disease
CA002523291A CA2523291A1 (en) 2003-04-23 2004-04-21 Tricyclic indole derivatives and their use in the treatment of alzheimer`s disease
CNA2004800175617A CN1809573A (zh) 2003-04-23 2004-04-21 三环吲哚衍生物和它们在治疗阿尔茨海默病中的用途
US10/553,878 US20060229302A1 (en) 2003-04-23 2004-04-21 Tricyclic indole derivatives and their use in the treatment of alzheimer's disease
JP2006505223A JP2006524206A (ja) 2003-04-23 2004-04-21 三環式インドール誘導体およびアルツハイマー病治療におけるそれらの使用法
BRPI0409622-3A BRPI0409622A (pt) 2003-04-23 2004-04-21 derivados tricìclicos de indol e o seu uso no tratamento da doença de alzheimer
RU2005136370/04A RU2005136370A (ru) 2003-04-23 2004-04-21 Трициклические индоловые производные и их применение в лечении болезни альцгеймера
MXPA05011365A MXPA05011365A (es) 2003-04-23 2004-04-21 Derivados triciclicos de indol y su uso en el tratamiento de la enfermedad de alzheimer.
ZA200508041A ZA200508041B (en) 2003-04-23 2005-10-05 Tricyclic indole derivatives and their use in the treatment of Alzheimer's disease
MA28563A MA27674A1 (fr) 2003-04-23 2005-10-19 Derives d'indole tricycliques et leur utilisation dans le cadre du traitement de la maladie d'alzheimer
CO05107375A CO5700829A2 (es) 2003-04-23 2005-10-21 Derivados triciclicos de indol y su uso en eltratamiento de la enfermedad de alzheimer
NO20055442A NO20055442L (no) 2003-04-23 2005-11-17 Trisykliske indolderivater og deres anvendelse ved behandling av Alzheimers sykdom
IS8135A IS8135A (is) 2003-04-23 2005-11-21 Þríhringtengdar indólafleiður og notkun þeirra til að meðhöndla Alzheimers-sjúkdóm

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0309221.0A GB0309221D0 (en) 2003-04-23 2003-04-23 Novel compounds

Publications (1)

Publication Number Publication Date
GB0309221D0 true GB0309221D0 (en) 2003-06-04

Family

ID=9957152

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0309221.0A Ceased GB0309221D0 (en) 2003-04-23 2003-04-23 Novel compounds

Country Status (16)

Country Link
US (1) US20060229302A1 (cg-RX-API-DMAC7.html)
EP (1) EP1620438A1 (cg-RX-API-DMAC7.html)
JP (1) JP2006524206A (cg-RX-API-DMAC7.html)
KR (1) KR20050111797A (cg-RX-API-DMAC7.html)
CN (1) CN1809573A (cg-RX-API-DMAC7.html)
BR (1) BRPI0409622A (cg-RX-API-DMAC7.html)
CA (1) CA2523291A1 (cg-RX-API-DMAC7.html)
CO (1) CO5700829A2 (cg-RX-API-DMAC7.html)
GB (1) GB0309221D0 (cg-RX-API-DMAC7.html)
IS (1) IS8135A (cg-RX-API-DMAC7.html)
MA (1) MA27674A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05011365A (cg-RX-API-DMAC7.html)
NO (1) NO20055442L (cg-RX-API-DMAC7.html)
RU (1) RU2005136370A (cg-RX-API-DMAC7.html)
WO (1) WO2004094430A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200508041B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1565428A1 (en) * 2002-11-27 2005-08-24 Elan Pharmaceuticals, Inc. Substituted ureas and carbamates
GB0328900D0 (en) * 2003-12-12 2004-01-14 Glaxo Group Ltd Novel compounds
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
GB0411404D0 (en) * 2004-05-21 2004-06-23 Glaxo Group Ltd Novel compounds
BRPI0515383A (pt) * 2004-09-21 2008-07-22 Pfizer Prod Inc n-etil hidroxietilamina útil no tratamento de condições do snc
GB0422766D0 (en) * 2004-10-13 2004-11-17 Glaxo Group Ltd Novel compounds
GB0422765D0 (en) * 2004-10-13 2004-11-17 Glaxo Group Ltd Novel compounds
GB0422755D0 (en) * 2004-10-13 2004-11-17 Glaxo Group Ltd Novel compounds
WO2006088705A1 (en) * 2005-02-14 2006-08-24 Wyeth Terphenyl guanidines as [beta symbol] -secretase inhibitors
GB0506562D0 (en) * 2005-03-31 2005-05-04 Glaxo Group Ltd Novel compounds
KR20080015079A (ko) 2005-04-08 2008-02-18 코멘티스, 인코포레이티드 베타 세크레타제 활성을 억제하는 화합물 및 이것의 사용방법
WO2007019078A2 (en) * 2005-08-03 2007-02-15 Merck & Co., Inc. Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease
WO2007061670A1 (en) * 2005-11-21 2007-05-31 Amgen Inc. Beta-secretase modulators and methods of use
US7872009B2 (en) 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
US7745484B2 (en) 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
US7838676B2 (en) * 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
TW200901991A (en) 2007-05-25 2009-01-16 Amgen Inc Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
MX2009012608A (es) 2007-05-25 2009-12-07 Amgen Inc Compuestos de hidroxietil amina substituidos como moduladores de beta-secretasa y metodos de uso.
FR2919288B1 (fr) * 2007-07-27 2009-09-04 Sanofi Aventis Sa Derives de 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6- carboxamides, leur preparation et leur application en therapeutique.
FR2919285B1 (fr) 2007-07-27 2012-08-31 Sanofi Aventis Derives de 1-oxo-isoindoline-4-carboxamides et de 1-oxo- 1,2,3,4-tetrahydroisoquinoleine-5-carboxamides, leur preparation et leur application en therapeutique.
ATE512968T1 (de) * 2007-07-27 2011-07-15 Sanofi Aventis 1,2,3,4-tetrahydropyrrolo(1,2-a)pyrazin-6- carboxamid und 2,3,4,5-tetrahydropyrrolo(1,2-a)- diazepin-7-carboxamid- derivate, ihre herstellung und therapeutische verwendung
FR2919286A1 (fr) 2007-07-27 2009-01-30 Sanofi Aventis Sa Derives de derives de 1-oxo-1,2-dihydroisoquinoleine-5- carboxamides et de 4-oxo-3,4-dihydroquinazoline-8- carboxamides,leur preparation et leur application en therapeutique.
FR2919289B1 (fr) * 2007-07-27 2009-09-04 Sanofi Aventis Sa Derives de 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]- diazepine-7-carboxamides, leur preparation et leur application en therapeutique.
US9096541B2 (en) 2012-03-29 2015-08-04 Oklahoma Medical Research Foundation Inhibition of memapsin 1 cleavage in the treatment of diabetes
EP3684767B1 (en) * 2017-09-22 2024-04-24 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
US12043631B2 (en) 2017-10-13 2024-07-23 Purdue Research Foundation BACE1 inhibitors for the treatment of Alzheimer's disease
US11214579B2 (en) 2017-10-13 2022-01-04 Purdue Research Foundation BACE1 inhibitors for the treatment of Alzheimer's disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033795A1 (en) * 1997-02-04 1998-08-06 The Regents Of The University Of California Nanomolar, non-peptide inhibitors of cathepsin d
US6207664B1 (en) * 1998-11-25 2001-03-27 Pfizer Inc. Squalene synthetase inhibitor agents
CA2410680A1 (en) * 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease

Also Published As

Publication number Publication date
WO2004094430A1 (en) 2004-11-04
CA2523291A1 (en) 2004-11-04
BRPI0409622A (pt) 2006-04-18
MA27674A1 (fr) 2005-12-01
EP1620438A1 (en) 2006-02-01
JP2006524206A (ja) 2006-10-26
US20060229302A1 (en) 2006-10-12
ZA200508041B (en) 2007-02-28
NO20055442L (no) 2005-11-17
AU2004232475A1 (en) 2004-11-04
MXPA05011365A (es) 2005-11-28
IS8135A (is) 2005-11-21
CO5700829A2 (es) 2006-11-30
KR20050111797A (ko) 2005-11-28
RU2005136370A (ru) 2006-05-27
CN1809573A (zh) 2006-07-26

Similar Documents

Publication Publication Date Title
GB0308114D0 (en) Novel compounds
GB0305918D0 (en) Novel compounds
GB0308186D0 (en) Novel compounds
GB0308185D0 (en) Novel compounds
GB0308333D0 (en) Novel compounds
GB0309221D0 (en) Novel compounds
GB0304424D0 (en) Novel compounds
EP1596860A4 (en) NEW CONNECTIONS
EP1648885A4 (en) NEW CONNECTIONS
GB0305426D0 (en) Novel compounds
GB0302431D0 (en) Novel compounds
GB0304809D0 (en) Novel compounds
GB0302546D0 (en) Novel compounds
GB0306213D0 (en) Novel compounds
GB0301592D0 (en) Novel compounds
GB0308187D0 (en) Novel compounds
GB0300481D0 (en) Novel compounds
GB0300482D0 (en) Novel compounds
GB0300483D0 (en) Novel compounds
GB0300484D0 (en) Novel compounds
GB0301480D0 (en) Novel compounds
GB0301955D0 (en) Novel compounds
GB0305564D0 (en) Novel compounds
GB0306212D0 (en) Novel compounds
GB0301589D0 (en) Novel compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)